From Yahoo Finance: 2025-03-22 10:30:00

Stifel lowered Maravai Lifesciences’ price target from $10 to $5, maintaining a Buy rating. Q4 revenues fell $1M short of expectations, while EBITDA missed by $7M. Management’s outlook is below expectations, but excludes high volume CleanCap orders. Stifel sees low visibility due to COVID transition, China uncertainty, and key model area opaqueness. Maravai looks undervalued at $2-$3, but remains a low-confidence Buy until better growth materializes.



Read more at Yahoo Finance: Maravai Lifesciences price target lowered to $5 from $10 at Stifel